[Protective effect of myosin light-chain kinase inhibitor on acute lung injury]

Jian-wen Bai1, Wei-wu Deng, Jian Zhang

  • 1Department of Emergency and Intensive Critical Medicine, Dongfang Hospital Affiliated to Tongji University, Shanghai 200120, China.

Abstract

Insights

Inhibiting myosin light-chain kinase (MLCK) with ML-7 protects human pulmonary arterial endothelial cells and reduces acute lung injury in mice. This suggests MLCK plays a key role in acute lung injury pathogenesis.

Area of Science:

  • Pulmonary medicine
  • Cell biology
  • Biochemistry

Context:

  • Lipopolysaccharide (LPS) challenge induces acute lung injury (ALI) and affects pulmonary endothelial cell function.
  • Myosin light-chain kinase (MLCK) is implicated in cellular responses to inflammatory stimuli.

Purpose:

  • To investigate the protective effects of an MLCK inhibitor (ML-7) against LPS-induced ALI in human pulmonary arterial endothelial cells (HPAECs) and in a mouse model.
  • To elucidate the role of MLCK activation in the pathogenesis of ALI.

Summary:

  • ML-7 treatment enhanced HPAEC viability and reduced phosphorylated MLCK (p-MLCK) levels post-LPS challenge.
  • In mice, ML-7 pretreatment attenuated LPS-induced lung injury, decreasing lung wet/dry ratio, bronchoalveolar lavage fluid protein, and myeloperoxidase activity.
  • ML-7 reduced neutrophil infiltration, pulmonary edema, hemorrhage, and expression of MLCK and CD11b in lung tissues.

Impact:

  • Inhibition of MLCK activation, by reducing myosin light chain phosphorylation, stabilizes vascular barrier function.
  • MLCK plays a critical role in the development of LPS-induced acute lung injury.
  • MLCK inhibitors represent a potential therapeutic strategy for managing ALI.

Related Concept Videos